SVB Securities Thinks Pardes Biosciences’ Stock is Going to Recover

In a report issued on May 2, Roanna Ruiz from SVB Securities maintained a Buy rating on Pardes Biosciences (PRDSResearch Report). The company’s shares closed last Tuesday at $7.47, close to its 52-week low of $5.54.

According to, Ruiz has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -27.3% and a 25.0% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Xeris Pharmaceuticals, and Atea Pharmaceuticals.

Currently, the analyst consensus on Pardes Biosciences is a Moderate Buy with an average price target of $25.00, which is a 228.9% upside from current levels. In a report issued on May 1, Jefferies also maintained a Buy rating on the stock with a $25.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

FS Development Corp II is a blank check company.

Read More on PRDS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More